Clinical trials: CONTROL Condition
Mammaplasty, Cicatrix
RN1001(Avotermin) in Scar Improvement Following Breast Augmentation
This will be a multi-centre, double-blind, within-subject, placebo controlled randomised trial in female subjects. All subjects will undergo bilateral breast augmentation surgery.
- Trial name
- NCT00436449
- Testing
- Avotermin
- Where
- 7 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Renovo
HIV Infections
A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels
IPM 012 is a double-blind, randomized, placebo-controlled phase I study conducted at one research center in Belgium among 36 healthy, HIV-negative women of 18-40 years of age, randomized in a 1:1:1 ratio to assess plasma, vaginal…
- Trial name
- NCT00613249
- Testing
- Dapivirine Gel 4750, 0.05%, 2.5g, Dapivirine Gel 4789, 0.05%, 2.5g
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Social Anxiety Disorder
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
The purpose of the study is to determine whether the PH94B nasal spray is effective for Acute Treatment of the symptoms of Social Anxiety Disorder (SAD) in adult men and women.
- Trial name
- NCT02622958
- Testing
- PH94B
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne…
- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases
- Trial name
- HOPE-3 (NCT05126758)
- Testing
- Deramiocel (CAP-1002)
- Where
- 20 sites in United States
- Volunteers
- 106 people
- Sponsor
- Capricor Inc.
Geographic Atrophy
A Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- CATALINA (NCT04465955)
- Testing
- NGM621
- Where
- 65 sites in United States
- Volunteers
- 320 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Post-Operative Pain
Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery
The purpose of this Phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, placebo-controlled study.
- Trial name
- NCT02489526
- Testing
- VVZ-149 Injections
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vivozon, Inc.
Polymyositis, Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients…
- Trial name
- PRESIDIO (NCT04033926)
- Testing
- KZR-616
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 25 people
- Sponsor
- Kezar Life Sciences, Inc.
Hypercholesterolemia
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with simvastatin on cholesterol levels in subjects with primary dyslipidemia
- Trial name
- NCT00256178
- Testing
- Lapaquistat acetate and simvastatin, Simvastatin
- Where
- 53 sites in Czechia, Estonia and 5 more
- Volunteers
- 411 people
- Sponsor
- Takeda
Obesity
ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
The purpose of this clinical research trial is to study safety and effectiveness of the TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered medically obese.
- Trial name
- NCT02518685
- Testing
- TransPyloric Shuttle, Lifestyle Counseling
- Where
- 9 sites in United States
- Volunteers
- 302 people
- Sponsor
- BaroNova, Inc.
Papillomavirus Infections
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)
Researchers want to learn if V503 (also called the 9-valent human papillomavirus [9vHPV] vaccine, recombinant) can induce an immune response to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Chinese females who previously…
- Trial name
- NCT07785843
- Testing
- V503
- Where
- China
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
PMS, Menstrual Cramp
A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome
This virtual, randomized, placebo-controlled clinical trial evaluates the effectiveness of a PMS capsule and PMS gummy in alleviating premenstrual syndrome symptoms over 12 weeks.
- Conditions
- PMS, Menstrual Cramp, Mood Change
- Trial name
- NCT06763809
- Testing
- PMS Capsule, PMS Gummy
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Semaine Health
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Troriluzole in Adult Participants With Spinocerebellar Ataxia
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3
- Trial name
- NCT03701399
- Testing
- troriluzole
- Where
- 23 sites in United States, China
- Volunteers
- 299 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Varicella (Chickenpox), Chickenpox Vaccine
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up…
- Trial name
- NCT07054099
- Testing
- MG1111 (Barycela inj.), VARIVAX™
- Where
- Thailand
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Interstitial Lung Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD.
- Trial name
- NCT05892614
- Testing
- efzofitimod 450 mg, efzofitimod 270 mg
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- aTyr Pharma, Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
- Trial name
- ENDURE (NCT00856284)
- Testing
- Alogliptin, Metformin, Glipizide
- Where
- 261 sites in United States, Argentina and 30 more
- Volunteers
- 2,639 people
- Sponsor
- Takeda
Renal Impairment, Hepatic Impairment
Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir
This is a multicenter, nonrandomized, open-label, parallel controlled Phase I clinical study to evaluate the Pharmacokinetics, Safety and Tolerability of SIM0417 combined with ritonavir after a single dose in subjects with mild…
- Trial name
- NCT05731804
- Testing
- SIM0417 600 mg; Ritonavir100 mg, SIM0417 375 mg; Ritonavir100 mg, SIM0417 750 mg; Ritonavir100 mg
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of DSP-8658 in patients with Type 2 diabetes mellitus and healthy adults.
- Trial name
- NCT01042106
- Testing
- DSP-8658
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period.
- Trial name
- EASIE (NCT00751114)
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 17 sites in United States, Austria and 15 more
- Volunteers
- 515 people
- Sponsor
- Sanofi
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR
- Trial name
- NCT01756716
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 50 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 49 people
- Sponsor
- Tanabe Pharma Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.